Nonsteroidal anti‐inflammatory drugs in acute viral respiratory tract infections: An updated systematic review

Azh, Nima; Barzkar, Farzaneh; Motamed-Gorji, Nogol; Pourvali-Talatappeh, Parmida; Moradi, Yousef; Azad, Roya Vesal; Ranjbar, Mahdy; Baradaran, Hamid Reza

doi:10.1002/prp2.925

Cited by 15 publications

(10 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… 2 , 5 An updated systematic review showed that in comparison to paracetamol, ibuprofen has a similar effect in fever control and recovery from the common cold in pediatric patients without a significant increase in gastrointestinal discomfort. 60 In a separate trial comprising 84,192 children, adverse events related to ibuprofen use at two differing doses were investigated and the risk of hospitalization for gastrointestinal bleeding or renal failure was found not to increase in comparison to the use of paracetamol. 61 However, although it is relatively safe in terms of other adverse events, ibuprofen is the most frequent cause of NSAID-induced hypersensitivity reactions in susceptible children.…”

Section: Introductionmentioning

confidence: 99%

NSAID Hypersensitivity in the Pediatric Population: Classification and Diagnostic Strategies

Cavkaytar¹,

Arga²

2022

JAA

View full text Add to dashboard Cite

Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most frequently administered drugs, mainly for their antipyretic, but also for pain-relieving and anti-inflammatory effects in children. NSAIDs are composed of structurally divergent subgroups of drugs with similar pharmacological and adverse effects. Aspirin originates from salicin and was the first synthesized analgesic. As a prototype of NSAIDs; aspirin-induced hypersensitivity reactions were first reported, but subsequently, other phenotypes of hypersensitivity reactions were also described with aspirin and other NSAIDs. There are certain challenging aspects of NSAID-hypersensitivity in the pediatric population that need to be further investigated. These include the effect of age on drug metabolism and the natural history of the various phenotypes of NSAID-hypersensitivity, the effect of certain co-factors (infections, exercise) on NSAID-hypersensitivity, and diagnostic clinical and laboratory biomarkers clarifying the endotypes. In recent years, a non-negligible number of case series, studies and expert panel reports have been published in this field with some novel features and diagnostic modalities in the pediatric population. With the current review; the clinical phenotypes and diagnostic and management modalities of suspected NSAID-induced hypersensitivity reactions in childhood and adolescence were explained and updated by examining past and current publications.

show abstract

Section: Introductionmentioning

confidence: 99%

NSAID Hypersensitivity in the Pediatric Population: Classification and Diagnostic Strategies

Cavkaytar¹,

Arga²

2022

JAA

View full text Add to dashboard Cite

show abstract

“…The most commonly used anti-inflammatory drugs are ibuprofen and paracetamol, whose safety profile makes their use widespread even in pediatric settings. Recent reviews examined the effectiveness of these drugs in fever, respiratory tract inflammation, and asthma, and concluded that a similar are rare when used for short periods (less than 7 days) [ 4 , 5 ]. Moreover, a meta-analysis including 19 studies found no significant difference between the two agents in the incidence of adverse events in pediatric patients [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

Adverse drugs reactions to paracetamol and ibuprofen in children: a 5-year report from a pediatric poison control center in Italy

et al. 2023

View full text Add to dashboard Cite

Background This study aimed to analyze all the patients who contacted the hospital’s pediatric poison control center (PPCC) for exposure to ibuprofen and acetaminophen, in order to assess the incidence of any adverse reactions. Methods We retrospectively reported the clinical data of children who accessed the PPCC of the Bambino Gesù Children’s Hospital, IRCCS, Rome, from January 1, 2018 to September 30, 2022 due to wrong, accidental or intentional intake of inappropriate doses of acetaminophen and/or ibuprofen. In addition, we compared patients according to the intake of one of the two drugs and reported the trimestral distribution of cases during the study period. Results A total of 351 patients accessed the PPCC during the study period. The median age was 3.0 years. Most patients were females (57.8%). The most common reason for inappropriate oral intake of paracetamol or ibuprofen was a wrong use or an accidental intake (78.6%), with a fifth of patients taking the drug with suicidal intent (21.1%). According to the PPCC evaluation, most patients were not intoxicated (70.4%). Hospitalization was required for 30.5% of patients. Adverse reactions were reported in 10.5% of cases, with a similar incidence in patients who took paracetamol or ibuprofen. Nausea and vomiting were the most commonly reported adverse reactions. A higher frequency of moderate intoxication was found in patients who took paracetamol compared to ibuprofen (p = 0.001). The likelihood of intoxication was also higher in the paracetamol cohort. A spike of cases was registered at the end of 2021. Conclusions We analyze exposures to the two most commonly used pediatric molecules, paracetamol and ibuprofen, to assess the frequency of adverse reactions. We demonstrated that these relatively “safe” drugs may be associated with intoxications and adverse reactions when inappropriately administered.

show abstract

“…[19][20][21] Therefore, searching reliable, secure, and natural methods for treatment of COVID and In uenza are continuing in the worldwide. [3,5,17,18,22] NCDs and COVID are spreading in countries with a higher rate of overweight. [10,[23][24][25][26][27] The Comprehensive Assessment of the Long-term Effects of Reducing Intake of Energy (CALERIE) phase 2 trial showed that moderate reduction of energy intake averaging approximately 12% over 2 years could improve markers of in ammation, cardiometabolic health, and oxidative stress in humans.…”

Section: Introductionmentioning

confidence: 99%

Weight loss treatment of COVID-19 in patients with NCDs: a pilot prospective clinical trial

Oshakbayev

Durmanova

Zhankalova

et al. 2023

Preprint

View full text Add to dashboard Cite

Background COVID-19 in comorbidity with non-communicable chronic diseases (NCDs) complicate the diagnosis, treatment, prognosis, and increase mortality rate. Objective. To evaluate the effects of the weight loss treatment on clinic/laboratory inflammation and metabolic profile, reactive oxygen species (ROS) body composition in patients with COVID-19 in comorbidity with NCDs. Design: A 6-week open, pilot prospective clinical trial. Setting: The study included 72 adult patients with COVID and influenza in comorbidity with type 2 diabetes (T2D), hypertension, and NASH. Interventions: The treatment involved a fast-weight-loss-method (Analimentary detoxication, ANADETO) including calorie restriction to 50–100 kcal/day, salt intake to 5–6 gr/day, hot water drinking 1000–1500 ml/day, walking > 2,000 steps/day, and sexual self-restraint. Main outcome measures: Primary endpoints: Clinic/infectious/inflammation tests for COVID/Influenza; weight loss during 14 days. Secondary endpoints: fasting blood glucose, HbA1c, blood insulin; systolic/diastolic BP; blood lipids; ALT/AST, chest-CT-scan. Results The patients weight lost from baseline (-9,14 − 12,4%; P < 0.001); COVID and Influenza were a negative in > 96.3% patients at the 14 days. Systolic/diastolic BP normalized (P < 0.0001), glucose/lipids metabolism (P < 0.0001); ALT/AST normalized (P < 0.0001), platelets increased from baseline (P < 0.0001), chest-CT (P < 0.0001) at 6-week follow-up. The previous antidiabetic, antihypertensive, anti-inflammatory and hepatoprotective, and other symptomatic medications were adequately decreased in 2–5 days to completely stopping by 5–8 days treatment. Conclusions The non-pharmacological treatment including fast weight loss is clinical/laboratory benefit in treatment of patients with COVID-19 and Influenza in comorbidity with T2D, hypertension, and NASH. Trial Registration: ClinicalTrials.gov NCT05635539 (12/01/2022): https://clinicaltrials.gov/ct2/show/NCT05635539?term=NCT05635539&draw=2&rank=1 .

show abstract

Nonsteroidal anti‐inflammatory drugs in acute viral respiratory tract infections: An updated systematic review

Cited by 15 publications

References 46 publications

NSAID Hypersensitivity in the Pediatric Population: Classification and Diagnostic Strategies

NSAID Hypersensitivity in the Pediatric Population: Classification and Diagnostic Strategies

Adverse drugs reactions to paracetamol and ibuprofen in children: a 5-year report from a pediatric poison control center in Italy

Weight loss treatment of COVID-19 in patients with NCDs: a pilot prospective clinical trial

Contact Info

Product

Resources

About